Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  buparlisib
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2303, NCI-2013-00017, 2012-002571-34, NCT01633060
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, NCT01816984
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120E2102, NCI-2013-02397, 2013-003129-27, NCT01934361
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120Z2402, NCI-2013-00832, 2012-002208-41, NCT01693614
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, UCSF CC# 115516, NCT01695473
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2203, NCI-2014-00219, NCT01816594
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2109, NCI-2015-00412, NCT02159066
PI3K Inhibitor BKM120, Carboplatin, and Paclitaxel in Treating Patients with Recurrent or Metastatic Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-192, NCI-2011-00228, NCT01297452
PI3K Inhibitor BKM120 or PI3K/mTOR Kinase Inhibitor BEZ235 and Capecitabine, Trastuzumab, or Lapatinib Ditosylate in Treating Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1024, NCI-2013-00951, NCT01300962
PI3K Inhibitor BKM120 and Everolimus in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1925-10, NCI-2012-00210, IRB00048549, NCT01470209
PI3K Inhibitor BKM120 and Combination Chemotherapy in Treating Patients with Advanced Refractory Solid Tumors or Metastatic Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1036, NCI-2013-01058, 11-1404, NCT01571024
PI3K Inhibitor BKM120 or PI3K Inhibitor BYL719 and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, NCT01623349
PI3K Inhibitor BKM120 and Rituximab in Treating Patients with Relapsed or Refractory Low-Grade B-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-13027, NCI-2014-00110, 2013C0156, NCT02049541
Buparlisib, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#239, NCI-2014-00218, 470970-1, CBKM120ZUS38T, NCT02194049
Start Over